Arcellx (NASDAQ:ACLX) Sees Strong Trading Volume – Still a Buy?

Arcellx, Inc. (NASDAQ:ACLX) shares saw strong trading volume on Tuesday . 4,739,269 shares changed hands during trading, an increase of 158% from the previous session’s volume of 1,833,981 shares.The stock last traded at $113.7530 and had previously closed at $113.75.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for $115.00 per share in cash plus a $5 contingent value right, valuing Arcellx at about $7.8 billion — a clear takeover premium and the primary reason the stock moved sharply higher. Reuters: Gilead to acquire Arcellx
• Positive Sentiment: Deal coverage and press releases from both companies reinforce the strategic rationale (Gilead boosting its oncology pipeline, specifically Anito-cel), sustaining investor interest and speculative buying ahead of closing. BusinessWire: Gilead press release
• Neutral Sentiment: HC Wainwright published FY2030 EPS projections (large positive EPS in their model) but maintains a Neutral rating and a $115 price objective — essentially aligned with the deal price and providing limited upside beyond the offer. MarketBeat: HC Wainwright note
• Neutral Sentiment: Some boutiques (e.g., Robert W. Baird) adjusted price targets close to the deal level while changing ratings — these moves signal analysts are re‑anchoring valuations to the transaction rather than issuing new bullish catalysts. The Fly: Baird note
• Negative Sentiment: Multiple sell- or hold-side analysts (Truist, Needham, Canaccord, Wells Fargo and others) downgraded ACLX to Hold/Equal Weight from Buy/Strong‑Buy; downgrades reduce near‑term buy-side conviction absent a higher takeover price or better deal terms. Benzinga: compilation of downgrades
• Negative Sentiment: Several law firms have launched shareholder investigations and class‑action alerts challenging whether the $115 + $5 CVR package is a fair price and whether the sale process was adequate — potential for litigation, delay, or settlement dynamics that could affect deal certainty and timing. BusinessWire: investor alert
• Negative Sentiment: Large prior institutional selling (Perceptive Advisors sold ~1M shares in Q4) is a reminder some holders have been reducing exposure; concentrated selling history could add pressure if deal sentiment fades. Fool: Perceptive Advisors sale

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Rothschild & Co Redburn cut shares of Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price objective on the stock. in a research note on Thursday, February 12th. William Blair downgraded shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research report on Monday. Canaccord Genuity Group set a $115.00 price target on shares of Arcellx in a research note on Monday. UBS Group lowered shares of Arcellx from a “buy” rating to a “neutral” rating and raised their price objective for the company from $100.00 to $115.00 in a research note on Tuesday. Finally, Guggenheim reissued a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Two analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Arcellx has an average rating of “Hold” and a consensus target price of $111.64.

Arcellx Trading Up 0.0%

The firm has a market capitalization of $6.58 billion, a P/E ratio of -28.96 and a beta of 0.36. The business’s fifty day moving average is $67.89 and its 200 day moving average is $75.07.

Insider Activity at Arcellx

In other news, insider Christopher Heery sold 5,882 shares of the firm’s stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the completion of the sale, the insider directly owned 23,749 shares of the company’s stock, valued at $1,627,043.99. This trade represents a 19.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcellx

Hedge funds and other institutional investors have recently modified their holdings of the stock. MAI Capital Management acquired a new stake in Arcellx during the 3rd quarter worth about $26,000. CWM LLC increased its position in shares of Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after acquiring an additional 251 shares in the last quarter. State of Wyoming acquired a new stake in shares of Arcellx during the second quarter valued at approximately $28,000. Ramirez Asset Management Inc. acquired a new stake in shares of Arcellx during the third quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after acquiring an additional 486 shares in the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.